All News

Vaccine2.jpg (keep)

EULAR 2026: Updated Recommendations for Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases

Jack Cush, MD

This update includes new pandemic era evidence, recombinant zoster vaccine data, and new perspectives on vaccination in patients taking novel immunosuppressants. Five overarching principles and 10 vaccine recommendations follow.

Read Article
Eular stage

Late-Breaking Studies at EULAR 2026

MedPage Today

Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical conc

Read Article
Risk Option Decision

Increased VTE Risk with Baricitinib

Jack Cush, MD

The RA-BRIDGE and RA-BRANCH studies were presented as a late-breaking abstract at EULAR 2026. This was the pooled results from two large FDA post-marketing commitment safety trials — RA-BRIDGE (global) and RA-BRANCH (US-only) — comparing baricitinib at 2 mg and 4 mg daily against TNF inhibitors (etanercept or adalimumab) in RA patients specifically enriched for venous thromboembolic event risk factors.

Read Article
Eular stage

From BiTE to TriTE: Progress of T-cell Engagers in RMDs

Md Yuzaiful Md Yusof, MRCP(UK), PhD

The EULAR 2026 Congress in London showcased growing interest in T-cell engagers as a novel strategy to achieve deep B-cell depletion and drug-free remission in refractory rheumatic and musculoskeletal diseases (RMDs).

Read Article
RheumNow Podcast square

EULAR 2026 Rheumatology RoundUp

Jack Cush, MD

It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.

Read Article
EULAR meeting room

NK Cells Without a CAR: AB-101 Is Neither CAR-T nor CAR-NK

Henrique Dalmolin, MD

Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route.

Read Article
Increased VTE Risk with Baricitinib The RA-BRIDGE and RA-BRANCH studies were presented as a late-breaking abstract at EULAR 2026 (LB0009). This was the pooled results from two large FDA post-marketing commitment safety trials — RA-BRIDGE (global) and RA-BRANCH (US-only) — https://t.co/5cQ829x77u
Dr. John Cush RheumNow ( View Tweet)
20% sample of elder RA Medicare pts (2009-2022) on TNFi who either stopped or tapered TNFi found 38% sustained de-escalation, while 62% re-escalated within a medianof 164. Re-escalation was more likely in Blacks, Hispanic/other, with a lower comorbidity burden. https://t.co/rEB3VdOii2
Dr. John Cush RheumNow ( View Tweet)
From BiTE to TriTE: Progress of T-cell Engagers in RMDs At EULAR 2026 in London, T-cell engagers drew attention as a strategy to achieve deep B-cell depletion and drug-free remission in refractory RMDs. BiTEs offer off-the-shelf availability, reversible toxicity from short https://t.co/o8Tn77aYRg
Dr. John Cush RheumNow ( View Tweet)
Danish hospital 574 newly diagnosed RA pt, 75% recv glucocorticoids (GC) in 1st yr (55% 1st visit) -- mean dose was 9.3 mg/day, with 46% recv oral tablets & 47% IA steriods injections. 20% had an infection in 1st Yr (RR 1.13; 0.77 to 1.67). Doses declined after 1st visit, but not https://t.co/JcerD61m0t
Dr. John Cush RheumNow ( View Tweet)
MTX: SC vs Oral? Metanalysis of 9 RCTs, 974 RA pts. Compared w/ oral, SC MTX signif. incr odds of ACR20 (RR=1.15), ACR50 (RR=1.14) & reduced GI adverse events (RR=0.58), diarrhea (RR=0.42): BUT no difference in ACR70, DAS28-ESR, bioavailability AUC, or other AE https://t.co/tQeQz7H7do
Dr. John Cush RheumNow ( View Tweet)
True or False: RA-associated ILD is considered one of the few RA outcomes that has not improved in the biologic era. See if you got it right in this week's RheumIQ quiz at https://t.co/Fnzn4UPu0n https://t.co/L7lAA6lwMp

Links:

Dr. John Cush RheumNow ( View Tweet)
Single center study of 102 pts starting JAK inhibitor (72% >50yrs; 77% RA) shows only 27.5% received at least one RZV vaccination dose (Shingrix) & only 3 recv RZV within 30 daysof a JAK inhibitor. ????? (I vaccinate everyone going on a JAKi w/ Shingrix - don't you?) https://t.co/j2jrBIiuOo
Dr. John Cush RheumNow ( View Tweet)
RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest RA inflammation may be under control, but RA-associated ILD remains a major challenge. At #EULAR2026, experts highlighted that ILD is one of the few RA outcomes not improving in the biologic era. Three new https://t.co/Qujhl3ktRp
Dr. John Cush RheumNow ( View Tweet)
RA-ILD: Screening risk and genetic susceptibility Two abstracts presented at EULAR 2026 add important insights into identifying patients at risk for RA-ILD and understanding the genetic mechanisms that may underpin disease development. https://t.co/IABp8NhUtS https://t.co/j8UHK2GRd7

Links:

Dr. John Cush RheumNow ( View Tweet)
When Patients with RA Choose Their Treatment, Outcomes Are Better — Here's the Data Dr. Aurelie Najm discusses abstract OP0204 presented in London at the EULAR 2026 Congress. https://t.co/hHQFffTXH0 https://t.co/tXv0SnGBz1

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR 2026 RA Topic Panel https://t.co/lLSL6FW9sg

Links:

Dr. John Cush RheumNow ( View Tweet)

Immune Dimming or Immune Reset in RA: How Far Should We Go? CD19 CAR T-cell therapy has moved from oncology to autoimmune disease after SLE reports of sustained drug-free remission suggesting an immune reset. This raises whether profound depletion is needed or if milder https://t.co/WONQmhs86j
Dr. John Cush RheumNow ( View Tweet)
Improving Referrals for Inflammatory Arthritis Dr. Antoni Chan discusses abstracts POS1284 and POS0784 presented at EULAR 2026 in London https://t.co/p1iT8yPNzF https://t.co/gEyuEwW4aj

Links:

Dr. John Cush RheumNow ( View Tweet)
Exploring Idiopathic Myopathies #EULAR2026: Idiopathic inflammatory myopathies (IIM) are a diverse group of autoimmune diseases with significant morbidity. While EULAR/ACR classification criteria were established in 2017, updated real-world data and better tools to assess https://t.co/CbUWodWT7z
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×